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Summary






Achieving precisely localized delivery of a drug – i.e. supplying a therapeutically active agent only where needed – has challenged chemists, pharmacologists and clinicians for over a century, since Paul Ehrlich coined the magic bullet concept. In response, a myriad of nanovehicles have been developed over the years as selective drug delivery vectors. However, there is a better and often overlooked alternative: rather than transporting the drug itself to the target, why not deliver a factory capable of making many copies of the drug instead?
One key development to fulfil this ambition has been the incorporation of bioorthogonal catalysts into nano delivery systems.1 A wealth of works has demonstrated in the last decade the capacity of various abiotic transition metals to catalyze new-to-life reactions in complex living environments.2 By loading these metals into man-made nanocarriers3-5 or biological vesicles,6 these multi-tasking systems can navigate into cells and perform synthetic tasks that are not genetically coded in living beings. Several groups have also explored the use of sophisticated gated systems to achieve temporal control of xenobiotic production by external stimuli,4,5 whereas others have focused on developing inactive substrates that can be converted into therapeutic agents exclusively by the action of such metals.6,7 In any case, the key requisite for these pharmaceutical nano-factories is their selective delivery to the site of the disease. To this end, camouflaging nanoparticles inside intercellular trafficking vehicles such as exosomes6 or under cell membranes8 is opening new avenues to address this challenging task.
Writing in Chem,9 Qu and co-workers report the development of a novel kind of multi-functional nanodevice designed to perform chirally-selective bioorthogonal transfer hydrogenation and be trafficked to sites of inflammation (Figure 1, left). The novel devices consist of mesoporous silica nanoparticles doped with Pd nanoparticles and a chiral auxiliary (MSN-Pd/CD nanoparticles) to mediate asymmetric catalysis. In addition, the particles were cloaked with neutrophil membranes (MSN-Pd/CD@Neu) to confer the capacity to target inflammatory processes in vivo. The authors show that, by adsorbing cinchona alkaloids on the surface of the metal, the novel devices display the capacity to mediate the enantioselective reduction of the double bond of achiral 2-aryl acrylic acids in the presence of external hydrogen donors (e.g. sodium formate). This newly gained capability was used to explore the synthesis of chiral drugs possessing an enantiomer with superior bioactivity, as it is the case of ibuprofen. The manufacturing compatibility of these nanodevices was demonstrated in vitro and in RAW264.7 cells, and confirmed in an inflammation model in vivo (Figure 1, right), where the in situ synthesized S-Ibuprofen was able to reduce the production of pro-inflammatory factor PGE2, alleviating inflammation in mouse paw.
	These results successfully show that it is possible to design a catalyst capable of performing chiral hydrogenations inside a membrane-cloaked nanoreactor. This membrane coating could, in principle, help to target inflammation sites and to avoid immune system detection. However, these aspects require further investigation, since it is yet unknown whether such a vector would be useful for systemic delivery. In this work, local injection at the inflammation region was performed without further biodistribution studies, probably because it was thought unlikely that the MSN-Pd/CD@Neu vectors would travel far from the injection site. It is also intriguing that the reactants (ibuprofen precursor and sodium formate) were supplied in separate MSN@Neu capsules (thus adding supplementary desorption and diffusion steps to the reaction process) rather than injected locally as free molecules. An attractive alternative could be to replace foreign hydrogen donors by natural sources (e.g. thiols) already present in the organism.
	There are also questions yet to be answered regarding the catalytic vehicle itself. Thus, it would be interesting to know the effect of the neutrophil membrane on the tradeoff between catalyst throughput and catalyst active life in the biological milieu: the membrane may reduce the reaction rate because of the additional diffusion resistance that it introduces for reactants and products, but - on the other hand - it is likely that the membrane may confer some degree protection against catalyst fouling and poisoning by biomolecules. This stresses the importance of the membrane coating and raises some important issues. For instance, the method of fabrication involves disruption of neutrophil cells in freeze-thaw cycles, then harvesting membrane components and coating MSN-Pd/CD particles. The purity of the membrane coating so obtained should be studied (and possibly optimized), as well as its adherence and stability on the nanoparticle. Finally, there is always the question of biodegradability of the vectors. MSN biodegradation rate is too low, and a more sensible alternative could involve breakable/biodegradable silica nanoparticles.10
In summary, despite the limitations of this early prototype and the improvements herein proposed, efforts to upgrade the functional capabilities of bioorthogonal catalysts are essential to progress the field to the ultimate goal of ringfencing pharmacotherapeutic interventions exclusively to diseased cells. The implementation of such nanotherapeutic regimens would improve the efficacy and reduce the systemic side effects of the treatment. By enabling the site-selective synthesis of a chiral drug for the first time, the work reported by Qu and coworkers advances towards this aim, representing an important contribution that expands the scope of bioorthogonal catalysts. 
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Figure 1. Preparation and use of the novel bioartificial nanodevices developed by Qu and coworkers. (Left) Stepwise functionalization of mesoporous silica nanoparticles to incorporate chiral catalytic properties (MSN + Palladium nanoparticles + cinchonidine alkaloid = MSN-Pd/CD) and chemotactic capabilities (MSN-Pd/CD + neutrophil membrane coating = MSN-Pd/CD@Neu). (Right) In vivo asymmetric synthesis of S-ibuprofen at sites of inflammation.

